brivudine has been researched along with Herpes-Genitalis* in 7 studies
2 review(s) available for brivudine and Herpes-Genitalis
Article | Year |
---|---|
Antiviral therapy of herpes simplex and varicella-zoster virus infections.
Antiviral treatment of herpesvirus infections is rapidly changing since the advent of new drugs with improved oral availability. The efficacy of valaciclovir, the prodrug of aciclovir, and famciclovir, the prodrug of penciclovir, in the treatment of herpes genitalis and acute herpes zoster has been well documented in large clinical trials. Both drugs are effective on zoster-associated pain. Brivudin and sorivudine which are the most active compounds against varicella-zoster virus (VZV) in cell culture have also been successful in the treatment of herpes zoster. Aciclovir is still the standard therapy of severe herpes simplex virus (HSV) and varicella virus infections. In patients treated with aciclovir, the mortality of herpes encephalitis has been reduced to about 25%. The development of resistance against aciclovir and the other nucleoside analogues has not been a problem to date in the treatment of immunocompetent individuals. However, in immunocompromised patients, aciclovir-resistant HSV strains often emerge. In such cases, intravenous foscarnet is the current treatment of choice. Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Antiviral Agents; Arabinofuranosyluracil; Bromodeoxyuridine; Chickenpox; Drug Resistance, Microbial; Encephalitis, Viral; Famciclovir; Herpes Genitalis; Herpes Labialis; Herpes Simplex; Herpes Zoster; Humans; Immunocompromised Host; Prodrugs; Simplexvirus; Valacyclovir; Valine | 1997 |
Antiviral chemotherapy.
Progress in antiviral chemotherapy has taken place as a logical strategy for the design of antiviral agents has emerged. The second-generation nucleoside analogues, led by acyclovir, have proved their worth against herpesviruses and should now become a standard part of medical practice. Meanwhile, recombinant DNA technology has lowered the cost of interferons to the point at which the several human subtypes of these naturally occurring hormones can be subjected individually to controlled clinical trials against the viral diseases in the treatment of which they show promise. Yet, optimism about the future of antiviral chemotherapy must be tempered by the observation that most of the agents discussed in this review are described more accurately as promising rather than proven, and several of these have not yet been released in Australia at the time of writing. Topics: Acyclovir; Amantadine; Animals; Antiviral Agents; Bromodeoxyuridine; Female; Hepatitis B; Herpes Genitalis; Herpes Simplex; Herpes Zoster; Humans; Idoxuridine; In Vitro Techniques; Interferons; Male; Neoplasms; Papillomaviridae; Respiratory Tract Infections; Ribavirin; Rimantadine; Tumor Virus Infections; Vidarabine | 1984 |
1 trial(s) available for brivudine and Herpes-Genitalis
Article | Year |
---|---|
[Antiviral chemotherapy].
After a discussion of the principles of antiviral chemotherapy, treatment and chemoprophylaxis of the following virus infections are reviewed in detail: the various manifestations of herpes simplex virus infections, varicella-zoster, cytomegalovirus infections, Epstein-Barr virus infections, laryngeal papillomas, and influenza A. Special reference is made to the treatment of immunocompromized patients. Acycloguanosine (acyclovir) has been found particularly useful in the treatment of herpes simplex virus and varicella zoster virus infections in immunocompromized patients and for herpesencephalitis. Varicella-zoster can also be treated effectively with bromovinyldeoxyuridine (BVDU). Toxicity of the currently used antiviral drugs is discussed as well as the problem of drug resistance. Topics: Acyclovir; Antiviral Agents; Bromodeoxyuridine; Chickenpox; Child; Clinical Trials as Topic; Cytomegalovirus Infections; Double-Blind Method; Encephalitis; Female; Herpes Genitalis; Herpes Simplex; Herpes Zoster; Humans; Immunologic Deficiency Syndromes; Infant, Newborn; Pemphigoid Gestationis; Pregnancy; Vidarabine; Virus Diseases | 1986 |
4 other study(ies) available for brivudine and Herpes-Genitalis
Article | Year |
---|---|
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
A series of tricyclic penciclovir (PCV) and hydroxybutylguanine (HBG) derivatives have been prepared with enhanced lipophilicity following an efficient synthetic route. All the novel tricyclic derivatives were evaluated for inhibitory activity against herpes simplex virus 1 and 2 (HSV-1, HSV-2) and thymidine kinase deficient (ACV resistant) HSV-1. The tricyclic HBG derivatives were devoid of inhibitory activity however several of the tricyclic PCV derivatives showed promising antiviral activity, in particular 9g (R = 4-MeO-C Topics: Acyclovir; Antiviral Agents; Guanine; Herpes Genitalis; Herpes Simplex; Herpesvirus 1, Human; Herpesvirus 2, Human; Humans; Models, Molecular | 2019 |
Pseudotumour of the tongue caused by herpes simplex virus type 2 in an HIV-1 infected immunosuppressed patient.
An HIV-1 infected immunosuppressed patient (CD4+ cell counts: 382 cells/microL; viral load 94,000 copies/mL) with recurrent perianal herpes simplex virus type 2 (HSV-2) infections is described, showing an unusual exophytic tumour resembling a squamous cell carcinoma in the lateral part of the tongue. He also had persistent facial herpes infection, oral candidosis, oral hairy leukoplakia and lymphadenopathy. The presence of HSV-2 was detected by polymerase chain reaction both in smears and in a tissue biopsy taken from the involved tongue area. Treatment with brivudin, a new oral virustatic drug, led to rapid regression of the tumour. Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Bromodeoxyuridine; Granuloma, Plasma Cell; Herpes Genitalis; HIV-1; Humans; Immunocompromised Host; Male; Tongue Diseases | 1998 |
Incidence of herpes simplex virus types 1 and 2 in penile lesions of college men.
Herpes simplex virus (HSV) was isolated from penile lesions of 15 college men. Using (E)-5-(2-bromovinyl)-2'-deoxyuridine sensitivity, monoclonal antibody immunofluorescence, and restriction endonuclease EcoRI digestion of viral DNA, 4 of 15 (26%) isolates were found to be HSV-1, and 11 of 15 (74%) isolates were found to be HSV-2. It is likely that some of the genital HSV-1 infections are related to oral genital contact, but this fact could not be established for all cases, since the females in this group had previously been shown to have a high incidence of genital HSV-1. Topics: Adult; Antibodies, Monoclonal; Antibodies, Viral; Bromodeoxyuridine; Deoxyribonuclease EcoRI; DNA Restriction Enzymes; DNA, Viral; Female; Herpes Genitalis; Humans; Male; Penile Diseases; Penis; Simplexvirus | 1984 |
Oral and topical treatment of experimental HSV-1 genital herpes with (E)-5-(2-bromovinyl)-2'-deoxyuridine.
A genital infection was induced in guinea pigs by intravaginal inoculation with herpes simplex virus type 1 and used to assess the efficacy of BVDU administered either orally or topically. Twice daily oral treatment with BVDU was effective in preventing or reducing the severity of disease if therapy was initiated 6 or 24 h post-infection, but was ineffective if compound was first administered 48 h post-infection. BVDU was also effective topically as 2% or 5% ointments but ineffective at 1%. Topical treatment with 5% ointment was beneficial when treatment was started within 24 h of infection but not effective if initiation of treatment was delayed further. Topics: Administration, Oral; Administration, Topical; Animals; Antiviral Agents; Bromodeoxyuridine; Female; Guinea Pigs; Herpes Genitalis; Male | 1984 |